Figure 1 | The Druggable Genome library contains the genes that are considered potential targets for therapeutics and is delivered as nine distinct subset siRNA libraries in the 96-well format. In the 384-well format, the first eight subsets are plated continuously to reduce partial plates. The Drug Targets portion includes genes involved with apoptosis, senesence, nucleic acid binding, autophagy, DNA repair, and characterized nuclear receptors.
Figure 2 | Target mRNA knockdown in a screen with siGENOME and ON-TARGETplus SMARTpool siRNA reagents was highly effective, even at concentrations of 2 nM. In extended studies, ON-TARGETplus also was effective in reducing false phenotypes due to off-targets.
Figure 3 | Our products offer more guaranteed siRNA reagents than any other provider to enable the broadest range of siRNA screening strategies. By leveraging the high-efficiency silencing of market-leading siRNA reagents, the execution of a Duet siRNA screen with two unique SMARTpool siRNA reagents (siGENOME and ON-TARGETplus) increases overall primary hit quality and reduces follow-up experimental time and effort.